呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

BORA III期延展试验证明阿斯利康IL-5单抗Fasenra对严重哮喘具有长期疗效

2018-09-18 MedSci MedSci原创

IL-5单抗哮喘阿斯利康
关注

阿斯利康近日公布了BORA III期延展试验的数据，该试验证明了Fasenra(benralizumab)对严重嗜酸性粒细胞性哮喘患者的辅助维持治疗的功效。

阿斯利康近日公布了BORA III期延展试验的数据，该试验证明了Fasenra(benralizumab)对严重嗜酸性粒细胞性哮喘患者的辅助维持治疗的功效。

在该试验中，Fasenra维持治疗56周，显示出与前期试验中相似的安全性和耐受性，并且Fasenra在III期试验SIROCCO或CALIMA中观察到的疗效指标的改善得以维持。先前接受安慰剂随后转为Fasenra治疗的患者的疗效结果与先前的研究结果也一致。

BORA的首席调查员，威斯康星大学医学与公共卫生学院过敏、肺和重症医学科医学教授William Busse博士评论说："作为一名临床医生，我对BORA试验结果感到兴奋，该结果证明了Fasenra可以实现严重哮喘患者的长期治疗。"

Fasenra是继葛兰素史克美泊利单抗（mepolizumab）及梯瓦 Cinqaero（reslizumab）之后第三个获批上市的白细胞介素-5（IL-5）的靶向药物。据阿斯利康称，Fasenra 是首个给药方案为8周的呼吸类生物药物。

SIROCCO和CALIMA的数据显示，Fasenra治疗4周后患者哮喘急性发作率降低51％，肺功能改善，FEV1变化高达159mL。并且该疗效持续整个治疗期。基于这一数据，Fasenra今年1月已经获得欧洲许可，用于辅助维持治疗严重嗜酸性粒细胞性哮喘。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-12-01 lujian

    #严重哮喘#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2019-01-04 gracezdd

    #FAS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2019-07-19 juliusluan78

    #III#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-20 zhangxingru

    #Fasenra#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-20 gjsgj

    #长期疗效#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-20 智智灵药

    #III期#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-20 bbjsj_1986

    #IL-5单抗#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-18 内科新手

    谢谢梅斯提供这么好的信息，学到很多

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1717840, encodeId=ffa41e178404b, content=<a href='/topic/show?id=e40c2116554' target=_blank style='color:#2F92EE;'>#严重哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21165, encryptionId=e40c2116554, topicName=严重哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4b932466782, createdName=lujian, createdTime=Sat Dec 01 15:40:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057963, encodeId=4b7c205e96373, content=<a href='/topic/show?id=3836e24819' target=_blank style='color:#2F92EE;'>#FAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7248, encryptionId=3836e24819, topicName=FAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Fri Jan 04 17:40:00 CST 2019, time=2019-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916038, encodeId=6599191603865, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jul 19 10:40:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271168, encodeId=62da12e1168e3, content=<a href='/topic/show?id=a2bee24989' target=_blank style='color:#2F92EE;'>#Fasenra#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7249, encryptionId=a2bee24989, topicName=Fasenra)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb0b97, createdName=zhangxingru, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553484, encodeId=cb8d1553484f5, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594534, encodeId=412a1594534f4, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631107, encodeId=3f29163110e2e, content=<a href='/topic/show?id=0bce96e6d5' target=_blank style='color:#2F92EE;'>#IL-5单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9676, encryptionId=0bce96e6d5, topicName=IL-5单抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=562b21684980, createdName=bbjsj_1986, createdTime=Thu Sep 20 10:40:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031907, encodeId=396f103190ed8, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Tue Sep 18 22:40:00 CST 2018, time=2018-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345555, encodeId=7ace3455553c, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Tue Sep 18 21:29:29 CST 2018, time=2018-09-18, status=1, ipAttribution=)]
    2018-09-18 医者仁心5538

    学习了

    0

相关资讯

重磅！梯瓦每月一次哮喘药新药Cinqaero获欧盟批准，GSK将临劲敌

全球仿制药巨头梯瓦（Teva）近日宣布，该公司研发的一款治疗哮喘的单抗药物Cinqaero（reslizumab）获得欧盟委员会（EC）批准，联合其他药物作为一种维持疗法，用于过去一年中发生至少一次哮喘发作（asthma exacerbation）的重度嗜酸性粒细胞性哮喘成人患者。在美国，reslizumab于2016年3月获FDA批准，其品牌名为Cinqair，该药也是继英国制药巨头葛兰素史克（